BRSK2 and metabolic syndrome: Among the 202 individuals with MetS, the reversion rate was 58.4% (59/101) in the SADA group and 45.5% (46/101) in the SAA group (RR: 1.30; 95% confidence interval [CI]: 1.03, 2.44, p = 0.047) (Fig. 3c).